JP2012523458A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523458A5
JP2012523458A5 JP2012506102A JP2012506102A JP2012523458A5 JP 2012523458 A5 JP2012523458 A5 JP 2012523458A5 JP 2012506102 A JP2012506102 A JP 2012506102A JP 2012506102 A JP2012506102 A JP 2012506102A JP 2012523458 A5 JP2012523458 A5 JP 2012523458A5
Authority
JP
Japan
Prior art keywords
group
dimethyl
composition according
acid moiety
enyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523458A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030799 external-priority patent/WO2010120711A1/en
Publication of JP2012523458A publication Critical patent/JP2012523458A/ja
Publication of JP2012523458A5 publication Critical patent/JP2012523458A5/ja
Pending legal-status Critical Current

Links

JP2012506102A 2009-04-13 2010-04-13 タンパク質ホスファターゼ2a活性化剤 Pending JP2012523458A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16875909P 2009-04-13 2009-04-13
US61/168,759 2009-04-13
PCT/US2010/030799 WO2010120711A1 (en) 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents

Publications (2)

Publication Number Publication Date
JP2012523458A JP2012523458A (ja) 2012-10-04
JP2012523458A5 true JP2012523458A5 (enExample) 2013-03-28

Family

ID=42981438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506102A Pending JP2012523458A (ja) 2009-04-13 2010-04-13 タンパク質ホスファターゼ2a活性化剤

Country Status (6)

Country Link
US (1) US8461362B2 (enExample)
EP (1) EP2419414A4 (enExample)
JP (1) JP2012523458A (enExample)
AU (1) AU2010236655A1 (enExample)
CA (1) CA2758823A1 (enExample)
WO (1) WO2010120711A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
JP2012523458A (ja) 2009-04-13 2012-10-04 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション タンパク質ホスファターゼ2a活性化剤
CA2759011A1 (en) * 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
US9220706B2 (en) 2012-06-01 2015-12-29 National Institutes Of Health (Nih) Inhibition of leukemic stem cells by PP2A activating agents
JP6757730B2 (ja) * 2014-12-31 2020-09-23 フリューダイム カナダ インコーポレイテッド マスサイトメトリーによる分析用の構造化生体試料
CN108779073A (zh) * 2015-06-23 2018-11-09 凯斯西储大学 用于治疗癌症的组合物和方法
BR112018002550A2 (en) 2015-08-10 2018-09-18 Dana-Farber Cancer Institute, Inc. inhibitor resistance mechanism

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2680749A (en) * 1951-12-01 1954-06-08 Eastman Kodak Co Water-soluble tocopherol derivatives
DE2822324C3 (de) * 1978-05-22 1981-02-26 Basf Ag, 6700 Ludwigshafen Herstellung von Vitamin-E-Trockenpulver
JPS59222415A (ja) 1983-05-31 1984-12-14 Kuraray Co Ltd 免疫調節剤
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis
WO1997024112A1 (en) * 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
IL142082A (en) * 1998-09-23 2005-12-18 Res Dev Tocoflowers, tocotrinols, derivatives as a novel and other side-chain and their uses
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6770672B1 (en) * 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
RU2263672C2 (ru) * 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
JP2002121132A (ja) * 2000-08-09 2002-04-23 Showa Denko Kk 発がん抑制剤および発がん抑制方法
US20040248971A1 (en) * 2001-07-27 2004-12-09 Shuyuan Yeh Use of vitamin e succinate and antiandrogen combination
US6858227B1 (en) * 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US20050215531A1 (en) * 2002-05-16 2005-09-29 Thomas Baumruker Use of edg receptor binding agents in cancer
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
RU2433117C2 (ru) * 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
AU2007217810B2 (en) * 2006-02-21 2012-10-11 The Ohio State University Research Foundation Anticancer agents
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
BRPI0715950A2 (pt) 2006-08-17 2013-07-30 Univ Chicago tratamento de doenÇas inflamatàrias
CA2663474C (en) * 2006-09-15 2017-06-27 Griffith University Pro-oxidant anti-cancer compounds
JP4481316B2 (ja) * 2007-01-09 2010-06-16 株式会社エヌ・ティ・ティ・ドコモ ユーザ装置および送信方法
BRPI0813683A2 (pt) * 2007-06-14 2019-09-24 Mitsubishi Tanabe Pharma Corp composto amina e uso farmacêutico do mesmo
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
JP2012523458A (ja) 2009-04-13 2012-10-04 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション タンパク質ホスファターゼ2a活性化剤
CA2759011A1 (en) * 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents

Similar Documents

Publication Publication Date Title
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
JP2010077141A5 (enExample)
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
JP2013542261A5 (enExample)
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
JP2014500861A5 (enExample)
JP2009530398A5 (enExample)
JP2015512943A5 (enExample)
BRPI0510414A (pt) uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
JP2016515561A5 (enExample)
JP2010265321A5 (enExample)
JP2013507423A5 (enExample)
JP2014513123A5 (enExample)
MX2010007375A (es) Nuevos derivados de lupano.
NZ609487A (en) Indoles as respiratory syncytial virus antiviral agents
JP2014515406A5 (enExample)
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
UA105229C2 (uk) Фармацевтичний склад
EP2590655A4 (en) COMPOUNDS AND METHOD FOR INHIBITING PHOSPHATE TRANSPORT
JP2015509075A5 (enExample)
HRP20210999T1 (hr) Derivati tirozina i pripravci koji ih sadrže
JP2017517547A5 (enExample)
ATE473221T1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus